Rezolute (RZLT) Projected to Post Earnings on Wednesday

Rezolute (NASDAQ:RZLT) is expected to post its Q2 2026 results before the market opens on Wednesday, February 11th. Analysts expect Rezolute to post earnings of ($0.16) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, February 10, 2026 at 4:00 PM ET.

Rezolute (NASDAQ:RZLT) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.09. On average, analysts expect Rezolute to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Rezolute Price Performance

Shares of NASDAQ RZLT opened at $3.15 on Wednesday. The stock’s fifty day moving average price is $4.14 and its two-hundred day moving average price is $6.68. Rezolute has a one year low of $1.07 and a one year high of $11.46. The firm has a market cap of $292.10 million, a price-to-earnings ratio of -3.39 and a beta of 0.46.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. BTIG Research reissued a “buy” rating and set a $5.00 target price on shares of Rezolute in a report on Thursday, January 8th. JMP Securities set a $17.00 price objective on shares of Rezolute in a research note on Wednesday, October 29th. Citigroup lowered shares of Rezolute from an “outperform” rating to a “market perform” rating in a report on Thursday, December 11th. Citizens Jmp downgraded shares of Rezolute from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 11th. Finally, HC Wainwright decreased their price objective on shares of Rezolute from $14.00 to $5.00 and set a “buy” rating on the stock in a research note on Friday, December 12th. Six research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Rezolute has a consensus rating of “Hold” and a consensus target price of $8.67.

Insiders Place Their Bets

In related news, CFO Daron Evans acquired 40,000 shares of the company’s stock in a transaction dated Monday, December 15th. The shares were purchased at an average price of $1.77 per share, for a total transaction of $70,800.00. Following the completion of the acquisition, the chief financial officer owned 415,900 shares of the company’s stock, valued at approximately $736,143. This trade represents a 10.64% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Nevan C. Elam bought 32,000 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The stock was purchased at an average cost of $1.59 per share, with a total value of $50,880.00. Following the completion of the transaction, the chief executive officer directly owned 641,119 shares in the company, valued at $1,019,379.21. This represents a 5.25% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased 89,100 shares of company stock valued at $150,232 over the last 90 days. 14.78% of the stock is currently owned by company insiders.

Institutional Trading of Rezolute

Several institutional investors and hedge funds have recently modified their holdings of the stock. Balyasny Asset Management L.P. bought a new position in shares of Rezolute in the third quarter valued at approximately $17,134,000. Rosalind Advisors Inc. bought a new position in Rezolute in the 2nd quarter valued at $7,766,000. Bank of America Corp DE increased its position in shares of Rezolute by 1,578.5% during the 3rd quarter. Bank of America Corp DE now owns 1,284,962 shares of the company’s stock valued at $12,079,000 after purchasing an additional 1,208,408 shares during the last quarter. Nantahala Capital Management LLC increased its position in shares of Rezolute by 77.4% during the 2nd quarter. Nantahala Capital Management LLC now owns 2,291,395 shares of the company’s stock valued at $10,220,000 after purchasing an additional 1,000,000 shares during the last quarter. Finally, Fred Alger Management LLC bought a new stake in shares of Rezolute during the 3rd quarter worth $5,240,000. 82.97% of the stock is owned by hedge funds and other institutional investors.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.